These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Sheikhha MH; Awan A; Tobal K; Liu Yin JA Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Chang WH Cancer; 2002 Jun; 94(12):3292-8. PubMed ID: 12115363 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254 [TBL] [Abstract][Full Text] [Related]
11. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362 [TBL] [Abstract][Full Text] [Related]
12. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. Marhäll A; Heidel F; Fischer T; Rönnstrand L Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308 [TBL] [Abstract][Full Text] [Related]
13. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029 [TBL] [Abstract][Full Text] [Related]
14. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908 [TBL] [Abstract][Full Text] [Related]
15. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Kiyoi H; Ohno R; Ueda R; Saito H; Naoe T Oncogene; 2002 Apr; 21(16):2555-63. PubMed ID: 11971190 [TBL] [Abstract][Full Text] [Related]
17. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Zhao M; Kiyoi H; Yamamoto Y; Ito M; Towatari M; Omura S; Kitamura T; Ueda R; Saito H; Naoe T Leukemia; 2000 Mar; 14(3):374-8. PubMed ID: 10720129 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia. Kang HJ; Hong SH; Kim IH; Park BK; Han KS; Cho HI; Shin HY; Ahn HS Leuk Res; 2005 Jun; 29(6):617-23. PubMed ID: 15863200 [TBL] [Abstract][Full Text] [Related]
19. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847 [TBL] [Abstract][Full Text] [Related]
20. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]